135 related articles for article (PubMed ID: 35395636)
41. The H3K36me2 writer-reader dependency in H3K27M-DIPG.
Yu JR; LeRoy G; Bready D; Frenster JD; Saldaña-Meyer R; Jin Y; Descostes N; Stafford JM; Placantonakis DG; Reinberg D
Sci Adv; 2021 Jul; 7(29):. PubMed ID: 34261657
[TBL] [Abstract][Full Text] [Related]
42. A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N; Poschke I; Lindner K; Bunse L; Mildenberger I; Boschert T; Jähne K; Green EW; Hülsmeyer I; Jünger S; Kessler T; Suwala AK; Eisele P; Breckwoldt MO; Vajkoczy P; Grauer OM; Herrlinger U; Tonn JC; Denk M; Sahm F; Bendszus M; von Deimling A; Winkler F; Wick W; Platten M; Sahm K
Nat Med; 2023 Oct; 29(10):2586-2592. PubMed ID: 37735561
[TBL] [Abstract][Full Text] [Related]
43. Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas.
Ballester LY; Wang Z; Shandilya S; Miettinen M; Burger PC; Eberhart CG; Rodriguez FJ; Raabe E; Nazarian J; Warren K; Quezado MM
Am J Surg Pathol; 2013 Sep; 37(9):1357-64. PubMed ID: 24076776
[TBL] [Abstract][Full Text] [Related]
44. High Level Immunoglobulin Gene Expression and Reduced Intra-tumoral Bacteria Associated With the Transition from Initial to Progressive Diffuse Intrinsic Pontine Glioma.
Gozlan EC; Huda TI; Quach JU; Varkhedi M; Desantis JE; Blanck G
Anticancer Res; 2024 Jun; 44(6):2325-2333. PubMed ID: 38821589
[TBL] [Abstract][Full Text] [Related]
45. Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
[TBL] [Abstract][Full Text] [Related]
46. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
[TBL] [Abstract][Full Text] [Related]
47. H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells.
Leszczynska KB; Freitas-Huhtamäki A; Jayaprakash C; Dzwigonska M; Vitorino FNL; Horth C; Wojnicki K; Gielniewski B; Szadkowska P; Kaza B; Nazarian J; Ciolkowski MK; Trubicka J; Grajkowska W; Garcia BA; Majewski J; Kaminska B; Mieczkowski J
Cell Rep; 2024 Feb; 43(2):113707. PubMed ID: 38306270
[TBL] [Abstract][Full Text] [Related]
48. Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges.
Mandorino M; Maitra A; Armenise D; Baldelli OM; Miciaccia M; Ferorelli S; Perrone MG; Scilimati A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791893
[TBL] [Abstract][Full Text] [Related]
49. Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence.
Sharma M; Barravecchia I; Teis R; Cruz J; Mumby R; Ziemke EK; Espinoza CE; Krishnamoorthy V; Magnuson B; Ljungman M; Koschmann C; Chandra J; Whitehead CE; Sebolt-Leopold JS; Galban S
Mol Cancer Ther; 2024 Jan; 23(1):24-34. PubMed ID: 37723046
[TBL] [Abstract][Full Text] [Related]
50. Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection.
Dal Bo M; Polano M; Ius T; Di Cintio F; Mondello A; Manini I; Pegolo E; Cesselli D; Di Loreto C; Skrap M; Toffoli G
J Transl Med; 2023 Jul; 21(1):450. PubMed ID: 37420248
[TBL] [Abstract][Full Text] [Related]
51. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.
Schuelke MR; Wongthida P; Thompson J; Kottke T; Driscoll CB; Huff AL; Shim KG; Coffey M; Pulido J; Evgin L; Vile RG
J Immunother Cancer; 2019 Jul; 7(1):188. PubMed ID: 31315671
[TBL] [Abstract][Full Text] [Related]
52. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
[TBL] [Abstract][Full Text] [Related]
53. Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma.
Bugiani M; Veldhuijzen van Zanten SEM; Caretti V; Schellen P; Aronica E; Noske DP; Vandertop WP; Kaspers GJL; van Vuurden DG; Wesseling P; Hulleman E
Oncotarget; 2017 Sep; 8(36):60447-60452. PubMed ID: 28947983
[TBL] [Abstract][Full Text] [Related]
54. The unique immune ecosystems in pediatric brain tumors: integrating single-cell and bulk RNA-sequencing.
Cao L; Xie W; Ma W; Zhao H; Wang J; Liang Z; Tian S; Wang B; Ma J
Front Immunol; 2023; 14():1238684. PubMed ID: 38094301
[TBL] [Abstract][Full Text] [Related]
55. H3
Auricchio AM; Pennisi G; Menna G; Olivi A; Gessi M; Gielen GH; Gaudino S; Montano N; Papacci F
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792513
[No Abstract] [Full Text] [Related]
56. Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression.
Wawrzuta D; Chojnacka M; Drogosiewicz M; Pędziwiatr K; Dembowska-Bagińska B
Strahlenther Onkol; 2024 May; ():. PubMed ID: 38748214
[TBL] [Abstract][Full Text] [Related]
57. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
[TBL] [Abstract][Full Text] [Related]
58. Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
Peterson ER; Sajjakulnukit P; Scott AJ; Heaslip C; Andren A; Wilder-Romans K; Zhou W; Palavalasa S; Korimerla N; Lin A; Obrien A; Kothari A; Zhao Z; Zhang L; Morgan MA; Venneti S; Koschmann C; Jabado N; Lyssiotis CA; Castro MG; Wahl DR
Res Sq; 2023 Sep; ():. PubMed ID: 37790517
[TBL] [Abstract][Full Text] [Related]
59. STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma.
Anderson JB; Bouchal SM; Zhang L; Daniels DJ
Oncotarget; 2023 Oct; 14():858-859. PubMed ID: 37791912
[No Abstract] [Full Text] [Related]
60. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.
Yoon HI; Wee CW; Kim YZ; Seo Y; Im JH; Dho YS; Kim KH; Hong JB; Park JS; Choi SH; Kim MS; Moon J; Hwang K; Park JE; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Sung KS; Song JH; Lee MH; Han MH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2021 Apr; 9(1):1-8. PubMed ID: 33913265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
